Clearmind Medicine Inc. has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, an MEAI-based oral drug candidate for Alcohol Use Disorder (AUD). The multinational, multicenter study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The second cohort, consisting of six patients across sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has completed treatment per protocol. Topline results from the second cohort are expected to be presented in the coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9625588-en) on January 14, 2026, and is solely responsible for the information contained therein.